Philip J. M. Brouwer

Author

Amsterdam University Medical Centers ORCID

Also Known As

James Ferguson, P.J.M. Brouwer, Peter Bonta, Philip Brouwer, Philip J M Brouwer, Philip J. M. Brouwer, Philip J.M. Brouwer, Philip JM Brouwer

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Amsterdam University Medical Centers University of Amsterdam Cornell University Scripps Research Institute International AIDS Vaccine Initiative

About

Philip J. M. Brouwer is an author at Amsterdam University Medical Centers specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	18	1.5K
2	Engineering	4	4	134
3	Biochemistry	2	2	77
4	Natural Sciences	1	1	20
5	Public Health	1	1	27

Philip J. M. Brouwer

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Philip J. M. Brouwer, Tom G. Caniels, Karlijn van der Straten, Science	2020	1.3K
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity Mads Delbo Larsen, Erik L. de Graaf, Myrthe E. Sonneveld, Science Humoral ResponseViral PathogenesisImmunologyImmunodominanceViral Responses	2020	396
High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages Willianne Hoepel, Hung‐Jen Chen, Chiara E. Geyer, Science Translational Medicine ImmunodeficienciesHumoral ResponseImmunologyImmunodominanceImmunologic Mechanism	2021	245
Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity Hejun Liu, Nicholas C. Wu, Meng Yuan, Immunity	2020	231
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle Philip J. M. Brouwer, Aleksandar Antanasijevic, Zachary T. Berndsen, Nature Communications	2019	207
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection Philip J. M. Brouwer, Mitch Brinkkemper, Pauline Maisonnasse, Cell VaccinationMucosal VaccinationCross-protectionVaccine DevelopmentSars-cov-2 Infection	2021	199
An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain Nicholas C. Wu, Meng Yuan, Hejun Liu, Cell Reports	2020	190
Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens George Ueda, Aleksandar Antanasijevic, Jorge A. Fallas, eLife	2020	181
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability Philip J. M. Brouwer, Tom G. Caniels, Karlijn van der Straten, Vaccine DevelopmentNon-rbd EpitopesVaccine ResearchVaccine TargetVaccine Surveillance	2020	153
Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence Kwinten Sliepen, Byung Woo Han, Ilja Bontjer, Nature Communications	2019	151

Page 1